NPC-14 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
113	Muscular dystrophy	2

113. Muscular dystrophy

---

Clinical trials : 622 /  Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JMA-IIA00134	14/08/2013	05/08/2013	Phase II study of nonsense readthrough compound NPC-14 (Arbekacin sulfate) to explore safety, tolerability, and efficacy in Duchenne muscular dystrophy patients (NORTH POLE DMD study)	Phase II study of nonsense readthrough compound NPC-14 (Arbekacin sulfate) to explore safety, tolerability, and efficacy in Duchenne muscular dystrophy patients (NORTH POLE DMD study)	Duchenne muscular dystrophy	Intervention type:DRUG. Intervention1:NPC-14, Dose form:INJECTION, Route of administration:INTRAVENOUS DRIP, intended dose regimen:Not applicable. Control intervention1:Placebo, Dose form:INJECTION, Route of administration:INTRAVENOUS DRIP, Intended dose regimen:Not applicable.	Yasuhiro Takeshima, MD, PhDHyogo College of Medicine Hospital, department of pediatrics	Not applicable	Completed	>=4 YEARS	No Limit	Male	21	Phase 2	Japan
2	NCT01918384 (ClinicalTrials.gov)	August 2013	1/8/2013	Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy	Phase II Study of Nonsense Readthrough Compound NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy Patients (NORTH POLE DMD Study)	Muscular Dystrophy, Duchenne	Drug: NPC-14;Drug: Placebo	Kobe University	Japan Medical Association;Nobelpharma	Active, not recruiting	4 Years	N/A	Male	21	Phase 2	Japan